In final draft guidance published today (7 March), NICE has recommended omalizumab (Xolair, Novartis Pharmaceuticals UK) as an option for treating severe, persistent allergic asthma in adults, ...
Bedfont ® outlines key updates and offers support for healthcare professionals navigating the changes. Bedfont ® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in ...
AstraZeneca's chief exec publicly criticized the U.K.'s tax policies last month, but that didn't stop officials there from backing the company's key asthma launch. England's National Institute for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results